僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Cantuzumab mertansine （SB-408075; huC242-DM1）, an ADC, is an immunoconjugate of the potent maytansine derivative （DM1; HY-19792） and the humanized monoclonal antibody （huC242） directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts